CA2096318A1 - 8-chloro-11-[1-[(5-methyl-3-pyridyl)methyl]-4-piperidyliden]-6,11-dihydro-5h-benzo[5,6]cyclohepta[1,2-b]pyridine - Google Patents

8-chloro-11-[1-[(5-methyl-3-pyridyl)methyl]-4-piperidyliden]-6,11-dihydro-5h-benzo[5,6]cyclohepta[1,2-b]pyridine

Info

Publication number
CA2096318A1
CA2096318A1 CA2096318A CA2096318A CA2096318A1 CA 2096318 A1 CA2096318 A1 CA 2096318A1 CA 2096318 A CA2096318 A CA 2096318A CA 2096318 A CA2096318 A CA 2096318A CA 2096318 A1 CA2096318 A1 CA 2096318A1
Authority
CA
Canada
Prior art keywords
methyl
piperidyliden
cyclohepta
benzo
pyridyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2096318A
Other languages
French (fr)
Other versions
CA2096318C (en
Inventor
Elena Carceller
Nuria Recasens
Carmen Almansa
Javier Bartroli
Manel Merlos
Marta Giral
Julian Garcia-Rafanell
Javier Forn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Noucor Health SA
Original Assignee
J Uriach y Cia SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by J Uriach y Cia SA filed Critical J Uriach y Cia SA
Publication of CA2096318A1 publication Critical patent/CA2096318A1/en
Application granted granted Critical
Publication of CA2096318C publication Critical patent/CA2096318C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)

Abstract

The present invention relates to 8-chloro-11-[1-[(5-methyl-3-pyridyl)methyl]-4-piperidyliden]-6,11-dihy dro-5H- benzo[5,6]cyclohepta[1,2-b]pyridine, to a process for its preparation and to pharmaceutical compositions containing it. This compound is a dual PAF antagonist and antihistamine.
CA002096318A 1992-05-22 1993-05-14 8-chloro-11-[1-[(5-methyl-3-pyridyl)methyl]-4-piperidyliden]-6,11-dihydro-5h-benzo[5,6]cyclohepta[1,2-b]pyridine Expired - Lifetime CA2096318C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES9201054 1992-05-22
ES09201054A ES2042421B1 (en) 1992-05-22 1992-05-22 PROCEDURE FOR OBTAINING 8-CHLORINE-11- * 1 - * (5-METHYL-3-PIRIDIL) METHYL * -4-PIPERIDILIDEN * -6,11-DIHYDRO-5H-BENZO * 5,6 * CYCLOHEPTA * 1 , 2-B * PIRIDINE.

Publications (2)

Publication Number Publication Date
CA2096318A1 true CA2096318A1 (en) 1993-11-23
CA2096318C CA2096318C (en) 1998-06-23

Family

ID=8277082

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002096318A Expired - Lifetime CA2096318C (en) 1992-05-22 1993-05-14 8-chloro-11-[1-[(5-methyl-3-pyridyl)methyl]-4-piperidyliden]-6,11-dihydro-5h-benzo[5,6]cyclohepta[1,2-b]pyridine

Country Status (13)

Country Link
US (2) US5407941A (en)
EP (1) EP0577957B1 (en)
JP (1) JP2730612B2 (en)
KR (1) KR0156518B1 (en)
AT (1) ATE124939T1 (en)
CA (1) CA2096318C (en)
DE (2) DE122008000031I2 (en)
DK (1) DK0577957T3 (en)
ES (2) ES2042421B1 (en)
HK (1) HK1006169A1 (en)
LU (1) LU91121I2 (en)
MX (1) MX9302958A (en)
NL (1) NL300384I2 (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5594021A (en) * 1993-05-20 1997-01-14 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin
US5962490A (en) * 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5514691A (en) * 1993-05-20 1996-05-07 Immunopharmaceutics, Inc. N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5591761A (en) * 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5571821A (en) * 1993-05-20 1996-11-05 Texas Biotechnology Corporation Sulfonamides and derivatives thereof that modulate the activity of endothelin
EP0626174A3 (en) * 1993-04-21 1996-01-03 Takeda Chemical Industries Ltd Methods and compositions for the prophylactic and/or therapeutic treatment of organ hypofunction.
US6613804B2 (en) 1993-05-20 2003-09-02 Encysive Pharmaceuticals, Inc. Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US6030991A (en) * 1993-05-20 2000-02-29 Texas Biotechnology Corp. Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6342610B2 (en) 1993-05-20 2002-01-29 Texas Biotechnology Corp. N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
ES2087818B1 (en) * 1993-11-24 1997-03-16 Uriach & Cia Sa J 8-CHLORINE-11- (1 - ((5-METHYL-3-PIRIDYL) METHYL) -4-PIPERIDYLIDEN) -6,11-DIHYDRO-5H-BENZO- (5,6) CYCLOHEPTAL (1,2-B) PIRIDINE, SMOKING.
JP3779349B2 (en) * 1995-04-24 2006-05-24 興和株式会社 Piperidine derivatives
US5977117A (en) * 1996-01-05 1999-11-02 Texas Biotechnology Corporation Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin
US5958905A (en) * 1996-03-26 1999-09-28 Texas Biotechnology Corporation Phosphoramidates, phosphinic amides and related compounds and the use thereof to modulate the activity of endothelin
US5804585A (en) * 1996-04-15 1998-09-08 Texas Biotechnology Corporation Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
ES2120899B1 (en) * 1996-10-07 1999-06-16 Uriach & Cia Sa J PROCEDURE FOR THE PREPARATION OF 8-CHLORO-6, 11-DIHYDRO-11- (1- (5-METHYL-3-PIRIDINYL) METHYL) -4-PIPERIDINYLIDENE) -5H-BENZO (5,6) CYCLOHEPTA (1, 2-B) PIRIDINE.
US5783705A (en) * 1997-04-28 1998-07-21 Texas Biotechnology Corporation Process of preparing alkali metal salys of hydrophobic sulfonamides
ES2241133T3 (en) 1997-04-28 2005-10-16 Encysive Pharmaceuticals Inc. SULFAMIDS FOR THE TREATMENT OF DISORDERS INDUCED BY ENDOTHELINE.
AU9683798A (en) * 1997-10-10 1999-05-03 Schering Corporation Ethyl 4-(8-chloro-5, 6-dihydro-11h- benzo{5,6}cyclohepta {1,2-b}pyridin -11-ylidene)-1- piperidene carboxylate polymorph
AU2277101A (en) * 1999-12-20 2001-07-03 Schering Corporation Stable extended release oral dosage composition
AU2276801A (en) 1999-12-20 2001-07-03 Schering Corporation Extended release oral dosage composition
US7405223B2 (en) 2000-02-03 2008-07-29 Schering Corporation Treating allergic and inflammatory conditions
WO2002018366A1 (en) * 2000-08-29 2002-03-07 Ranbaxy Laboratories Limited Process for the synthesis of n-(5-methylnicotinoyl)-4-hydroxypiperidine, a key intermediate of rupatadine
US20040242619A1 (en) * 2003-03-12 2004-12-02 Toth Zoltan G. Processes for preparation of polymorphic forms of desloratadine
JP3881640B2 (en) * 2003-08-08 2007-02-14 塩野義製薬株式会社 Dry syrup containing loratadine
WO2006103688A1 (en) * 2005-04-01 2006-10-05 Hetero Drugs Limited A novel crystalline form of rupatadine free base
WO2006114676A2 (en) * 2005-04-27 2006-11-02 Cadila Pharmaceuticals Limited A process for the preparation of rupatadine
US20070036859A1 (en) * 2005-08-11 2007-02-15 Perry Ronald L Sustained release antihistamine and decongestant composition
CN101497606B (en) * 2008-01-29 2014-04-02 东莞达信生物技术有限公司 Preparation of rupatadine or salt thereof
PL2588472T3 (en) 2010-06-30 2014-09-30 J Uriach Y Compania S A RUPATADINE derivative AS AN ANTIHISTAMINIC AGENT
AR082049A1 (en) 2010-06-30 2012-11-07 Uriach & Cia Sa J LIQUID FORMULATIONS OF RUPATADINA FUMARATO
EP2727919B1 (en) * 2011-06-28 2019-05-08 Fujian Mindong Rejuvenation Pharmaceutical Co., Ltd. Benzocycloheptanethiophene derivatives for anti-allergic reactions
CN102653535A (en) * 2011-12-09 2012-09-05 东莞达信生物技术有限公司 Rupatadine free alkali and preparation method thereof
EP2824103B1 (en) 2013-07-09 2016-04-27 Cadila Pharmaceuticals Limited An improved process for the preparation of Rupatadine Fumarate
US10463656B2 (en) 2017-01-05 2019-11-05 Iowa State University Research Foundation, Inc. Methods and compositions for prevention of feedlot bovine respiratory disease
TWI825013B (en) 2017-04-19 2023-12-11 日商帝國製藥股份有限公司 Patches containing rupatadine
CN109096251B (en) * 2018-09-26 2020-11-03 合肥医工医药股份有限公司 Compound with dual histamine receptor antagonistic activity and application
CN109734702B (en) * 2019-03-01 2020-07-03 南京工业大学 Method for preparing rupatadine fumarate by adopting micro-channel reaction device
WO2021086133A1 (en) * 2019-10-31 2021-05-06 (주)제이디바이오사이언스 Tricyclic compound and pharmaceutical use thereof
JP2023549381A (en) 2020-11-18 2023-11-24 バイオファーマ・シナジーズ，エス．エル． Orodispersible powder compositions containing antihistamine active compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4282233B1 (en) * 1980-06-19 2000-09-05 Schering Corp Antihistaminic 11-(4-piperidylidene)-5h-benzoÄ5,6Ü-cyclohepta-Ä1,2Ü-pyridines
JPS61501205A (en) * 1984-02-15 1986-06-19 シェリング・コ−ポレ−ション 8↓-chloro↓-6,11↓-dihydro↓-11↓-(4↓-piperidylidene)↓-5H↓-benzo[5,6]cyclohepta[1,2-b]pyridine and its salts, compounds thereof and pharmaceutical compositions containing these compounds.
US4826853A (en) * 1986-10-31 1989-05-02 Schering Corporation 6,11-Dihydro-11-(N-substituted-4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-B)pyridines and compositions and methods of use
US5089496A (en) * 1986-10-31 1992-02-18 Schering Corporation Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies
WO1989010363A1 (en) * 1988-04-28 1989-11-02 Schering Corporation Fused polycyclic compounds, compositions, methods of manufacture and their use as paf antagonists, antihistamines and/or antiinflammatory agents
CA2004211A1 (en) * 1988-11-30 1990-05-31 Masataka Syoji Piperidine derivatives and hyportensives containing the same
IE68935B1 (en) * 1990-06-22 1996-07-24 Schering Corp Bis-benzo or benzopyrido cyclohepta piperidene piperidylidene and piperazine compounds compositions and methods of use
GB9102997D0 (en) * 1991-02-13 1991-03-27 Pfizer Ltd Therapeutic agents
US5360907A (en) * 1993-06-14 1994-11-01 G.D. Searle & Co. Pyrrolo[3,2-B]pyridinylalkyl benzamide derivatives

Also Published As

Publication number Publication date
NL300384I2 (en) 2009-08-03
US5407941A (en) 1995-04-18
DE69300255D1 (en) 1995-08-17
EP0577957B1 (en) 1995-07-12
NL300384I1 (en) 2009-06-02
DE122008000031I1 (en) 2008-10-02
CA2096318C (en) 1998-06-23
ES2042421A1 (en) 1993-12-01
DE122008000031I2 (en) 2010-12-30
JP2730612B2 (en) 1998-03-25
MX9302958A (en) 1993-11-01
ES2042421B1 (en) 1994-08-01
KR0156518B1 (en) 1998-11-16
US5476856A (en) 1995-12-19
DK0577957T3 (en) 1995-12-04
EP0577957A1 (en) 1994-01-12
DE69300255T2 (en) 1996-01-04
LU91121I2 (en) 2005-01-03
JPH0687856A (en) 1994-03-29
HK1006169A1 (en) 1999-02-12
ES2076817T3 (en) 1995-11-01
KR930023359A (en) 1993-12-18
ATE124939T1 (en) 1995-07-15

Similar Documents

Publication Publication Date Title
CA2096318A1 (en) 8-chloro-11-[1-[(5-methyl-3-pyridyl)methyl]-4-piperidyliden]-6,11-dihydro-5h-benzo[5,6]cyclohepta[1,2-b]pyridine
DE3573600D1 (en) 8-chloro-6,11-dihydro-11-(4-piperidylidene)-5h-benzoû5,6¨cyclohepta-û1,2-b¨pyridine and its salts, processes for the production thereof and pharmaceutical compositions containing these compounds
HUP0003305A3 (en) Hiv protease inhibiting tetrahydro-pyrimid-2-on derivative, pharmaceutical compositions containing it and process for producing the compound
HU9302726D0 (en) Piperidine derivatives, process for producing them and pharmaceutical preparations containing these compounds
CA2105071A1 (en) Use of nicotinic analogs for treatment of degenerative diseases of the nervous system
AU1594892A (en) New benzopyran compounds, process for preparing these and pharmaceutical compositions containing them
HU202520B (en) Process for producing 6,11-dihydro-11-(4-piperidinylidene)-5h-benzo (5,6) cyclohepta (1,2-b) pyridines and pharmaceutical compositions comprising same
HU9402187D0 (en) Heterocyclic compounds, process for producing them and pharmaceutical compositions containing them
EG19361A (en) A process for the preparation of piperidine compound having local anaesthetica and analgetic
AU8854091A (en) Bis-benzo cyclohepta piperidylidene, piperidine and piperazine compounds, compositions and methods of use
NZ501417A (en) Crystalline polymorphs of descarbonylethoxyloratadine (8-chloro-6, 11-dihydro-11-(4-piperidylidene)-5H-benzo[5,6] cyclohepta[1,2-b]pyridine) and methods for their use
HU9402462D0 (en) Process for the preparation of 0-[4-(4-piperidinyl)butyl]-tyrosine derivatives as fibrinogen receptor antagonists
AU3611093A (en) Substituted furo(3',4':6,7)indolizino(1,2-b)quinolinones
ES2087818A1 (en) 8-chloro-11-[1-[(5-methyl-3-pyridyl)-methyl]-4- piperidylidene]-6,11-dihydro-5H-benzo-[5,6]-cycloheptal-[1,2- b]-pyridine fumarate
NO20005485D0 (en) Oral preparations containing 8-chloro-6,11-dihydro-11- (4-piperylidene) -5H-benzo- [5,6] cyclohepta [1,2-b] pyridine
AU3876293A (en) New heterocyclic compounds, a process for the preparation thereof, and pharmaceutical compositions containing them
HUP0004457A3 (en) Angiogenesis inhibiting thiadiazolyl-pyridazine derivatives, process for producing them and pharmaceutical compositions containing the same
HUT68064A (en) Process for preparing hexahydrobenzo[f]quinolinones
ES2087026A1 (en) New benzo[5,6]cyclohepta-[1,2-b]pyridine derivative
AU9683798A (en) Ethyl 4-(8-chloro-5, 6-dihydro-11h- benzo{5,6}cyclohepta {1,2-b}pyridin -11-ylidene)-1- piperidene carboxylate polymorph
EP0637960A4 (en) SUBSTITUTED INDOLIZINO 1,2-b]QUINOLINONES.
HU9204112D0 (en) Method for producing new benzole derivatives condensed with 5-member ring as well as pharmaceutical preparatives containing these compounds
HU9201206D0 (en) 5,7-dihydroxi-2-methyl-8-[4-(3-hydroxi-1-(1-propyl)-piperidinyl]-4h-1-benzopyrane-4-one derivatives as well as methods for producing said compounds and pharmaceutical preparatives containing them
AU7025800A (en) Process for the preparation of 1-methyl-3-carbomethoxy-4-(4'-fluorophenyl)-piperidine
AU2673588A (en) 1,4-dihydropyridine derivatives as neuroprotective compounds

Legal Events

Date Code Title Description
EEER Examination request